The Man Whose Antidepressants Stopped Working The case invol

The Man Whose Antidepressants Stopped Working The case involves a 63-year-old man suffering from severe depression and anxiety, with a history of recurrent episodes and previous response to pharmacotherapy. His primary concerns encompass persistent depressive symptoms that have proven resistant to multiple medication trials, prompting an evaluation of potential underlying causes and treatment adjustments. The comprehensive assessment includes exploring his current symptoms, psychosocial stressors, medical history, and family history of depression, aiming to inform an accurate diagnosis and optimal approach to management.

Initial clinical questions focus on understanding his present mental state, including feelings of hopelessness, thoughts of self-harm, and impact on daily functioning. Exploring psychosocial factors such as recent life events, social support, and interpersonal relationships is essential, as social support has been evidenced as a protective factor against depression (Gulf Bend Center, n.d.a). Additionally, involving family members in psychoeducation can enhance treatment adherence and provide crucial support, especially considering his recurrent, treatment-resistant depression. Empirical evidence supports combining pharmacotherapy with psychotherapy—particularly cognitive-behavioral therapy (CBT)—as a first-line approach for depression management, as CBT targets dysfunctional thoughts and maladaptive behaviors contributing to depressive symptoms (Ng, How, & Ng, 2017).

Physical examination and laboratory assessments are vital to rule out secondary causes of depression, such as thyroid dysfunction. Routine screening for thyroid abnormalities is recommended because hypothyroidism can present with depressive features, particularly with elevated TSH and normal T4 levels (Samuels, 2018). For this patient, tests for infectious, metabolic, or autoimmune conditions should also be conducted to exclude other etiologies. The use of general screening tools like the General Health Questionnaire (GHQ) can help monitor symptom severity and short-term psychiatric fluctuations (Gulf Bend Center, n.d.a).

Considering his history of multiple depressive episodes, differential diagnoses include mood disorder due to another medical condition, adjustment disorder with depressed mood, and melancholic features of major depressive disorder (MDD). The clinical presentation aligns most closely with MDD with melancholic features, characterized by pervasive anhedonia, worse in the morning, early awakening, significant weight loss, guilt, and psychomotor retardation. The severity and resistance to treatment raise concerns about disease progression and neurobiological changes associated with aging and chronic depression (Stahl,

2013).

Pharmacologically, the patient has previously responded to venlafaxine XR, a serotonin-norepinephrine reuptake inhibitor (SNRI). However, discontinuing it prematurely contributed to relapse and possibly precipitated tolerance or resistance. Reintroduction or escalating to higher doses of SNRIs might be considered, but given his ongoing resistance, switching to or augmenting with other classes like tricyclic antidepressants (TCAs) or monoamine oxidase inhibitors (MAOIs) could be beneficial. Despite their side effect profiles, these medications remain effective second- and third-line options for treatment-resistant depression. TCAs act by antagonizing multiple serotonin and norepinephrine receptors, while MAOIs inhibit enzymatic breakdown of neurotransmitters, increasing synaptic levels (Stahl, 2013).

In this context, combination therapy involving psychotherapy and pharmacotherapy appears most promising. Evidence suggests that long-term antidepressant use may be necessary for recurrent cases, with psychotherapy facilitating skill development to maintain remission and prevent relapse. Regular follow-up, medication titration, and close monitoring for side effects are essential. Awareness of potential risks, such as hypertensive crises with MAOIs or anticholinergic effects with TCAs, guides safe prescribing practices (Stahl, 2013). Ultimately, individualized treatment plans that incorporate patient preferences, comorbidities, and social factors are key to effective depression management in older adults.

References Gulf Bend Center. (n.d.a). Depression: Depression & related conditions basic information. Retrieved from https://gulfbendcenter.org Ng, C. W. M., How, C. H., & Ng, Y. P. (2017). Managing depression in primary care. Singapore Medical Journal, 58(8). https://doi.org/10.11622/smedj.2017088 Samuels, M. H. (2018). Subclinical hypothyroidism and depression: Is there a link? The Journal of Clinical Endocrinology & Metabolism, 103(5). https://doi.org/10.1210/jc.

Stahl, S. M. (2013). Stahl’s essential psychopharmacology: Neuroscientific basis and practical application (4th ed.). Cambridge University Press.